Richard H. Chapple

Apr 22, 2024 | biorxiv.org | Richard H. Chapple |Xueying Liu |Sivaraman Natarajan |Margaret Alexander

AbstractNeuroblastoma is a common pediatric cancer, where preclinical studies suggest that a mesenchymal-like gene expression program contributes to chemotherapy resistance. However, clinical outcomes remain poor, implying we need a better understanding of the relationship between patient tumor heterogeneity and preclinical models. Here, we generated single-cell RNA-seq maps of neuroblastoma cell lines, patient-derived xenograft models (PDX), and a genetically engineered mouse model (GEMM).

Nov 12, 2023 | nature.com | Hyeong-Min Lee |Min Pan |Duane Currier |Richard H. Chapple |Xueying Liu |Jacob Steele | +6 more

AbstractCombination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating a genetic map of druggable genes that sensitize cells to commonly used chemotherapeutics.

Apr 14, 2023 | biorxiv.org | Richard H. Chapple |Xueying Liu |Sivaraman Natarajan |Margaret Alexander

AbstractNeuroblastoma is a common pediatric cancer, where preclinical studies have suggested chemotherapy resistance is driven by a mesenchymal-like gene expression program. However, the poor clinical outcomes imply we need a better understanding of the relationship between patient tumors and preclinical models. Here, we generated single-cell RNA-seq maps of neuroblastoma cell lines, patient-derived xenograft models (PDX), and a genetically engineered mouse model (GEMM).